Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICASO: Effect of PCSK9 Inhibitors on Calcific Aortic Stenosis
NCT07256197Phase 3Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in calcific aortic stenosis (AS), sponsored by Beijing An Zhen Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
calcific aortic stenosis (AS)
Beyond the preview
Go deeper on NCT07256197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256197.